Since late 2020, the 340B Drug Pricing Program has faced increasing challenges—particularly for covered entities relying on contract...

The Drug Supply Chain Security Act (DCSCA), a critical piece of legislation aimed at securing the pharmaceutical supply chain, has...

AbbVie, a global biopharmaceutical company, recently made headlines by ceasing to offer 340B ceiling prices effective August 1, 2024, for...

In healthcare, accessibility, and affordability are pivotal pillars for ensuring that individuals receive the treatment and medications...

The 340B Drug Pricing Program is crucial in expanding access to affordable medications for eligible healthcare organizations serving...

As of April 1st, 2024, 32 drug manufacturers have implemented various contract pharmacy restrictions for Covered Entities within the 340B...

340B PATIENTS ACT Federal Legislation On March 12, 2024, legislators unveiled a new federal bill that addresses systemic barriers to...

The 340B Drug Pricing Program has been instrumental in ensuring access to affordable medications for vulnerable populations across the...

The Inflation Reduction Act, a legislative initiative aimed at curbing inflation, has sparked significant discourse within various...